| Patient-derived xenograft models in cancer therapy: technologies and applications Y Liu, W Wu, C Cai, H Zhang, H Shen, Y Han Signal Transduction and targeted therapy 8 (1), 160, 2023 | 190 | 2023 |
| A comprehensive analysis of the efficacy and safety of COVID-19 vaccines C Cai, Y Peng, E Shen, Q Huang, Y Chen, P Liu, C Guo, Z Feng, L Gao, ... Molecular Therapy 29 (9), 2794-2805, 2021 | 169 | 2021 |
| Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes W Wu, Y Liu, S Zeng, Y Han, H Shen Journal of hematology & oncology 14, 1-28, 2021 | 61 | 2021 |
| The efficacy of COVID-19 vaccines against the B. 1.617. 2 (delta) variant C Cai, Y Liu, S Zeng, H Shen, Y Han Molecular Therapy 29 (10), 2890-2892, 2021 | 18 | 2021 |
| Novel insights into noncanonical open reading frames in cancer Y Liu, S Zeng, M Wu Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1877 (4), 188755, 2022 | 17 | 2022 |
| Discovery of LLC0424 as a Potent and Selective in Vivo NSD2 PROTAC Degrader L Liu, A Parolia, Y Liu, C Hou, T He, Y Qiao, S Eyunni, J Luo, C Li, ... Journal of Medicinal Chemistry 67 (9), 6938-6951, 2024 | 7 | 2024 |
| NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis A Parolia, S Eyunni, BK Verma, E Young, Y Liu, L Liu, J George, S Aras, ... Nature Genetics 56 (10), 2132-2143, 2024 | 6 | 2024 |
